iShares Neuroscience and Healthcare ETF
IBRN
2 hedge funds and large institutions have $2.64M invested in iShares Neuroscience and Healthcare ETF in 2024 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 3 closing their positions.
8.81% less ownership
Funds ownership: 77.96% → 69.15% (-8.8%)
10% less capital invested
Capital invested by funds: $2.93M → $2.64M (-$291K)
60% less funds holding
Funds holding: 5 → 2 (-3)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$212K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$254K |
| 2 |
FTUS
Flow Traders U.S.
New York
|
-$244K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$32.4K |
IBRN Hedge Fund Activity: Q4 2024 in Review
2 of the 7,606 institutional investors tracked by Wall St. Rank reported a position in iShares Neuroscience and Healthcare ETF (IBRN) for Q4 2024, worth a combined $2.64M — down 9.9% from $2.93M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of IBRN and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was BlackRock, adding an estimated $212K. The largest seller was Jane Street, exiting entirely with an estimated $254K sold.
- 2 institutional investors held iShares Neuroscience and Healthcare ETF (IBRN) as of Q4 2024, down from 5 in Q3 2024.
- Funds reported $2.64M of iShares Neuroscience and Healthcare ETF stock for Q4 2024, down 9.9% quarter-over-quarter.
- 0 funds opened new iShares Neuroscience and Healthcare ETF positions in Q4 2024 and 3 closed out, a net change of -3 holders.
- The largest iShares Neuroscience and Healthcare ETF buyer in Q4 2024 was BlackRock, an estimated $212K added.
- The largest iShares Neuroscience and Healthcare ETF seller in Q4 2024 was Jane Street, an estimated $254K sold.
Based on aggregated 13F filings for Q4 2024.